IMPORTANT COVID-19 INFORMATION

Maryland ENT Center News

Baltimore Magazine recognizes Alan Shikani MD FACS as TOP DOC 2012, 2013, 2015, 2016, 2017, 2018, 2019 and 2020

Dr. Shikani is the director of the Maryland Nose and Sinus Center and Rhinology Fellowship Program. Since 2006, fellows have some from different areas of the world and spent an entire year training in rhinology under Dr. Shikani's tutelage.

About Dr. Alan Shikani:

Alan ShikaniAlan H. Shikani, MD, FACS, FARS: clinician, researcher, teacher and inventor is a most accomplished physician in the field of otolaryngology. Dr. Shikani completed his residency and fellowship training at the Johns Hopkins department of Otolaryngology-Head and Neck Surgery (according to US News, Johns Hopkins has been the top Otolaryngology-Head and Neck Surgery program in the United States for the last 30 years). Dr. Shikani serves as chief of the Division of Otolaryngology-Head and Neck Surgery of Union Memorial Hospital in Baltimore, chief of the Division of Otolaryngology-Head the and Neck Surgery at Good Samaritan Hospital and chief of the Division of Otolaryngology-Head the and Neck Surgery at LifeBridge Sinai Hospital.

Dr. Shikani specializes in the field of Rhinology which covers all aspects of nose and sinus diseases. He is also the founder and director of the Maryland Nose and Sinus Rhinology Fellowship Program, which was the first Rhinology fellowship program established in Maryland in 2006 (there are only 33 Rhinology programs in the world). Dr. Shikani continuously striving to improve his surgical skills and the precision of his technique and procedures; he has performed over 15,000 nasal procedures over a 35 year career, including endoscopic sinus surgery & balloon sinuplasty for sinusitis, correction of nasal septal deviation & radiofrequency coblation of the turbinates for nasal obstruction and snoring, cosmetic rhinoplasty for correction of nasal deformity.

Dr. Shikani was named Baltimore Top Doc in 2012, 2013, 2015 and 2016, 2017, 2018, 2019 and 2020.

For more information, you can contact the Maryland Nose & Sinus Center (410) 321-1025 or 410-554 NOSE (6673).


Maryland Nose and Sinus Center Rhinology Fellowship Program

Dr. Shikani established the Maryland Nose and Sinus Center Rhinology Fellowship Program in Baltimore in 2006; since then numerous rhinology fellows have applied from the US and from different areas of the world to come and train with us, including applicants from Lebanon, Switzerland, Syria, Greece, Jordan, Ireland, Israel, Qatar and India. Some of our graduates have decided to stay in in the United States and established themselves as leaders in rhinology, while others have returned home to establish successful rhinology teaching programs in their own countries.

It has been said: "The important things are the lives we touch; the people we help get better". Being able to mentor and influence the future of young otolaryngologists from all over the world has been one of the most rewarding experiences in my career. Alan H. Shikani MD, FACS.


Alan Shikani, MD, Receives Award from the National Medical Society AAO-HNS

Alexandria, VA - Alan Shikani, MD, of Baltimore, MD, received the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) Honors Award and was recognized during the AAO-HNSF 2012 Annual Meeting & OTO EXPO at the Walter E. Washington Convention Center in Washington, DC, September 9 - 12. The AAO-HNS presents the Honors Awards to medical professionals in recognition of extensive meritorious service through the presentation of instructional courses, scientific papers, participation on any AAO-HNS/F committee or in an Academy leadership position. Dr. Shikani is currently at Maryland ENT in Baltimore, MD. The AAO-HNSF 2012 Annual Meeting & OTO EXPO is the largest gathering of otolaryngologists in the world.

About the AAO-HNS

The American Academy of Otolaryngology - Head and Neck Surgery (www.entnet.org), one of the oldest medical associations in the nation, represents nearly 12,000 physicians and allied health professionals who specialize in the diagnosis and treatment of disorders of the ears, nose, throat, and related structures of the head and neck. The Academy serves its members by facilitating the advancement of the science and art of medicine related to otolaryngology and by representing the specialty in governmental and socioeconomic issues.


IFOS, South Korea

Dr. Shikani was invited to Seoul, South Korea on June 1-5, 2013, by the International federation of Oto- Rhino-laryngological Societies, to be the Chair and Moderator of a seminar on "Topical Therapy for Chronic Rhinosinusitis" and also to be present their novel research paper on "In-Office Balloon Sinuplasty, the new Frontier for treatment of Nasal polyps".


Discovery & Innovation

Dr. Shikani has made numerous inventions which are currently on the market and have to date improved the lives of countless ENT patients. Dr. Shikani currently holds twenty patents in his name, either individually or as a co-inventor, and he has founded a bio-tech company start-up the Airway Company which manufactures speaking valves and heat moisture exchangers (HMEs) for tracheotomy patients. Dr. Shikani has published numerous publications in peer review journals and books and made numerous presentations in national and international meetings. He has developed several devices that are now widely used in field of otolaryngology (listed below).

The Shikani Middle Meatal Antrostomy Stent: While a resident at The Johns Hopkins Hospital, Dr. Shikani invented a new sinus stent (the Shikani Middle Meatal Antrostomy Stent*) that is used to prevent adhesions following endoscopic sinus surgery. Adhesions are the most common complication of sinus surgery that causes sinusitis to recur). Thousands of patients worldwide have benefited from the Shikani Middle Meatal Antrostomy Stent.

Stent

*Shikani, A. : A New Middle meatal antrostomy Stent For Endoscopic Sinus Surgery. Laryngoscope. 104: 638-641, 1994

*Shikani A: A middle Meatal Antrostomy Stent for Pediatric Endoscopic Sinus Surgery Am J Rhinology 10 (4): 225-228, 1996

The Shikani Tracheotomy Speaking Valve: Tracheotomy patients, who otherwise may be unable to speak, are helped by the Shikani Tracheotomy Speaking Valve* to recover their ability to communicate and talk. The valve requires less effort and more easily tolerated than any other speaking valve on the market. The Shikani Tracheotomy Heat Moisture Exchanger (HME) has a unique design that allows air to flow through in a turbulent pattern, which greatly increases the efficiency. as compared to other HME's on the market. Both devices are manufactured by the Airway Company Inc., a Biotech start -up founded by Dr. Shikani, which mission is helping people breathe and improving the quality of life of tracheotomy patients.

Shikani Speaking Valve + Shikani HME - Animation Video

New unidirectional airflow ball tracheostomy speaking valve. Otolaryngol Head Neck Surg. 2000 Jul;123(1 Pt 1):103-7.

Comparison of speech parameters and olfaction using different tracheotomy speaking valves. Int Forum Allergy Rhinol. 2012 Jul-Aug;2(4):348-53.

Experimental Assessment and Future Applications of the Shikani Tracheostomy Speaking Valve. American Journal of Speech-Language Pathology, November 2015, Vol. 24:733-738. doi:10.1044/2015_AJSLP-14-0115

The Shikani Tracheotomy Speaking Valve

The Shikani Tracheotomy Speaking Valve

The Shikani Tracheotomy Speaking Valve and the Shikani Tracheotomy Heat Moisture Exchanger (HME) are named for Dr. Shikani's pioneering work in the field of voice disorders.

The Shikani Optical Stylet (SOS):

The Shikani Optical Stylet

The Shikani Optical Stylet (manufactured by Clarus Medical, Minnesota)

The Shikani Optical Stylet

Dr. Shikani using the Shikani Optical Stylet for intubation

Shikani Optical Stylet (SOS): he Shikani Optical Stylet* was designed 1999 as a malleable, fiberoptic stylet to be used for difficult intubations. The Clarus Shikani has become the cornerstone of the Clarus line of difficult airway devices, and a popular tool for physicians worldwide. Otolaryngologists, anesthesiologists and emergency physicians are using the Shikani Optical Stylet to provide immediate, clear visualization of the airway. The Stylet is especially helpful for difficult intubations and for correct placement of endotracheal tubes. Dr. Shikani also invented a new method of intubation using the SOS, which allows doctors to intubate without any Macintosh laryngoscope blade, hence avoding the risk of injuring the lips, teeth or larynx.

The Shikani Seeing Stylet for difficult intubation in children: initial experience

*Shikani A: A New Scope-Stylet for Management of the Difficult Airway. Otolaryngol. Head Neck Surg., 120(1): 113-116, 1999.

The Shikani Technique of intubation with the Shikani Optical Stylet


Baltimore Ravens

As the official medical team of the Baltimore Ravens, the Union Memorial Hospital offers the region's best in sports medicine, doctors and services. In his position of chief of Otolaryngology-Head and Neck Surgery at Union Memorial Hospital, Dr. Shikani is the Otolaryngologist of the Baltimore Ravens team. He has treated several of the Ravens NFL players and coaches.


The Shikani-El Hibri Prize for Discovery & Innovation at Johns Hopkins

In 2014, Alan H. Shikani, MD, founder and president of the Maryland ENT Center, and Fuad El-Hibri, founder and chair of Emergent BioSolutions established the Shikani/El Hibri Prize for Discovery & Innovation at the Johns Hopkins Bloomberg School of Public Health (JHSPH). This annual $10,000 prize recognizes excellence in the laboratory sciences and discoveries that have the potential to significantly advance biomedical science and to translate into improvements to patient care or the public's health. "The Prize for Discovery and Innovation" explained Dr. Shikani and Mr El-Hibri "demonstrates our commitment to the extraordinary faculty at JHSPH and to support young teachers-scholars who dedicate themselves to academic excellence and creative pursuit. Our hope is that the Shikani/El-HibriPrize will inspire others to want to make a difference and support the new generation of Hopkins researchers."

Inspired by the impact of the Johns Hopkins School's work in public health, his own academic connections with Johns Hopkins and his son's (Henry Shikani) degree in Molecular Microbiology and Immunology at the Bloomberg School of Public Health, Dr. Shikani felt motivated to support those researchers whose works caries the potential to translate critical knowledge of laboratory research into the clinic and public health.

Having founded Emergent BioSolutions, a global specialty biopharmaceutical company whose corporate mission is to protect and enhance life, Mr. El-Hibri has dedicated his life work to advancing public health. "Instilling in our youth the love for discovery and innovation will help ensure a steady stream of scientific leaders. We hope that investing in today's faculty and scholars will lead to identifying new cures and treatments for tomorrow."

Recipients of the Shikani/El Hibri Prize for Discovery & Innovation at Johns Hopkins include:

2014 Recipient: The 2014 recipient is Dr. Jiou Wang, from the Department of Biochemistry & Molecular Biology of the JHSPH for his work: A novel, unifying mechanism for the molecular pathogenesis of Amyotrophic Lateral Sclerosis (ALS,or Lou Gehrig's disease) and Fronto-Temporal Dementia (FTD). By analyzing the mutation's structure at the RNA and DNA levels and identifying the causes of interference with protein production in diseased cells, Wang's team found the probable root cause of ALS. This exciting work has recently been published in Nature: "C9orf72 nucleotide repeat structures initiate molecular cascades of disease. 2014 Mar 13;507(7491):195-200."

Scott Bailey
Jiou Wang
Department of Biochemistry & Molecular Biology

2015 Recipient: The 2015 recipient is Dr. Scott Bailey, from the Department of Molecular Microbiology and Immunology and the Malaria Research Institute of the JHSPH for his work: Understanding the molecular mechanisms underlying the CRISPR-based system of bacterial immunity. Scott and his team were the first to fully reconstitute the E. coli CRISPR system in vitro, which enabled them to distinguish the biochemical steps involved in the identification and destruction of invading DNA (but not host DNA). They also determined the high-resolution structure of Cascade bound to a ssDNA target, a technical tour-de-force that provides a molecular blueprint for understanding the mechanisms of the CRISPR system. This exception la work was recently accepted for publication at the very prestigious journal Science: "Targeted Destruction, How the bacterial CRIPR immune system recognizes foreign DNA."

Scott Bailey
Dr. Scott Bailey
Department of Molecular Microbiology and Immunology

2016 Recipient: The 2016 recipient is Dr. Andrew Pekosz, from the W. Harry Feinstone Department of Molecular Microbiology and Immunology of the JHSPH for his work: "Restricted replication of the live attenuated influenza A virus vaccine during infection of primary differentiated human nasal epithelial cells". One of the principle ways Dr. Pekosz is contributing to our basic research efforts is through the use of primary human nasal epithelial cell (hNEC) cultures to study influenza virus replication and cellular responses to infection. This culture system is capable of discerning changes in the replication of various clinical isolates in a way that no other standard cell culture system is capable of, which is allowing JH-CEIRS to be able to differentiate different influenza virus isolates as to their fitness for spreading in the human population and will become an important tool to assess the "pandemic potential" - the threat a particular animal influenza virus carries for becoming a human pathogen - of a number of animal influenza viruses that are being isolated at other CEIRS facilities Dr. Pekosz's knowledge of influenza biology and his use of hNEC cultures are indispensable for the JH-CEIRS work we are moving forward in a way that bridges clinical studies, basic research and public health. His studies of LAIV replication in hNEC cultures fit perfectly into this description. He is providing molecular and mechanistic insights into LAIV replication using a novel culture system and his research could lead to better influenza vaccines, which are sorely needed. This exciting work was recently published in Vaccine: 33 (2015) 4495-4504.

Andrew Pekosz
Andrew Pekosz PhD
Co-Director, Johns Hopkins Center of Excellence in Influenza Research and Surveillance (JH-CEIRS), Director, Center for Emerging Viruses and Infectious Diseases (CEVID)

2016 Shikani/El Hibri prize
Left to Right: Andrew Pekosz PhD (Professor, Molecular Microbiology and Immunology), Micheal Klag MD (Dean, Johns Hopkins Bloomberg School of Public Health), Fuad ElHibri, Alan Shikani MD, Arturo Casadevall, PhD (Chair, Molecular Microbiology and Immunology). May 2016

2017 Recipient: The 2017 recipient is Dr. Daniela Drummond Barbosa from the Department of Biochemistry and Molecular Biology for her work on germ stem cell production, maintenance and differentiation in the ovary as a function of environmental exposures (dietary influences in particular) and also as a function of organismic-level regulatory relationships with other key organs already was at the time, and continues to be, cutting edge, highly innovative, rigorous, and very impactful. The specific piece of work for which Daniela is being nominated for the Shikani/El-Hibri prize is her recent demonstration that the sensing of amino acids, which are the building blocks for proteins, by adult adipocytes modulates the maintenance of female germ stem cells in the ovary, thus providing a hitherto unknown metabolic link between adipose tissue and the ovary and furthering the connection between diet, metabolism and egg production. The work was published in a very substantive, three-authors article published in the journal Development, a leading and prestigious journal in the field of developmental biology. To quote Daniela (cf. essay appended with this nomination), "this study reveals a new step in the adipocyte-stem cell crosstalk, and suggests that the aberrant co-option of endocrine pathways that normally tie stem cell lineages to whole body physiology might contribute to the increased cancer risk associated with obesity." Daniela has clearly evolved into a word class leader in the use of Drosophila as a powerful and relevant model system for the study of complex biology in a way that is highly relevant to reproduction and public health.

Daniela Drummond Barbosa
Daniela Drummond Barbosa
Professor Department of Biochemistry and Molecular Biology

2017 Shikani/El Hibri prize
Left to Right: Micheal Klag MD (Dean, Johns Hopkins Bloomberg School of Public Health), Henry Shikani PhD, Alan Shikani MD, Daniela Drummond Barbosa, PhD, Fuad ElHibri. May 2017

2018 Recipient: The 2018 recipient is Dr. George Dimopoulos, from the Department of Molecular Microbiology and Immunology for his innovative and creative research leading to the development and discovery of genetically modified malaria-resistant mosquitoes that can spread and prevail in a mosquito population. This work has a profound potential for malaria control and public health. Dr. Dimopoulos' research stands out through its innovation and creativity, with the long-term goal of developing new strategies to stop transmission of malaria, dengue and Zika by mosquitoes. He joined our department in 2003 after an extremely successful training trajectory in laboratories of some of the best institutions in the world, including Stockholm University, University of Crete, Harvard University and the European Molecular Biology Laboratory. As a faculty member, he has occupied positions at the Imperial College of London and at Johns Hopkins University. George has played a leading role in the advancement of cutting-edge mosquito research, and his work has been published in many top-ranking scientific journals including Nature, Science, Cell Host & Microbe, PLoS Biology, PNAS, etc. His discoveries have also been highlighted numerous times in media such as the NYT, BBC, NPR, Voice of America, Smithsonian, Discovery channel, Scientific American, Wired, etc, and one of his discoveries relating to the mosquito microbiome was highlighted by the Discover Magazine as #13 of the top 100 Science discoveries of 2011. Based on this knowledge, his research group at Johns Hopkins University has developed genetically modified immune-enhanced mosquitoes that can resist infection with these pathogens. This line of research has a strong potential to evolve into a self-sustainable disease transmission-blocking strategy relying on genetically modified pathogen-resistant mosquitoes that would replace those that currently transmit disease. This discovery represents a significant advance in the basic science and understanding of the tripartite interactions between mosquito immunity, microbiota and mating behavior, and has a profound translational potential with relevance to public health.

George Dimopoulos
George Dimopoulos, PhD
Professor in the Department of Molecular Microbiology and Immunology

2018 Shikani/El Hibri prize
Left to Right: Ellen MacKenzie MD (Dean, Johns Hopkins Bloomberg School of Public Health), James Jackson PhD, Alan Shikani MD, George Dimopoulos, PhD, Fuad ElHibri. August 2018

2019 Recipient: The 2019 recipient is Dr. Anthony Leung from the Department of Biochemistry and Molecular Biology for his work on three breakthrough discoveries: The first is in recognition of his development of transformative proteomics-based approaches to study poly(ADP)-ribosylation by mapping site-specific modifications on target proteins. The second is for the surprising discovery of a family of enzymes expressed in chikungunya and other pathogenic viruses that reverse poly(ADP)-ribosylation of proteins modified in virus infected cells. Anthony's laboratory, in collaboration with Dr. Diane Griffin, showed that these enzymes are essential for virus replication and virulence in mouse models and thus represent promising new targets for anti-viral therapies. The third is in recognition of yet another breakthrough from Anthony's laboratory, namely the invention of new technology for labeling poly(ADP)-ribose polymers and poly(ADP)- ribosylated proteins. As described in Anthony's published manuscript, this breakthrough invention will greatly accelerate basic science discoveries related to understanding poly(ADP)- ribosylation functions in health and disease, as well as advance clinical and translational research efforts to target poly(ADP)-ribosylation for therapeutic purposes.

Dr. Anthony Leung's research has provided valuable new insights into the molecular and cellular functions of PARylation, as well as greatly needed new research tools for studying this important protein modification. Because of its underlying connections with cancer, neurodegeneration, cardiovascular disease, asthma and viral infection, Anthony's work on PARylation well propel efforts to target this pathway for novel therapeutic purposes with potentially major public health benefits.

Anthony Leung
Anthony K. L. Leung, PhD
Associate Professor, Department of Biochemistry and Molecular Biology

2019 Shikani/Leung
Ellen MacKenzie MD (Dean, Johns Hopkins Bloomberg School of Public Health), Patrick Shikani, Szcolt Harsanyi PhD, Alan Shikani MD, Anthony K. L. Leung, PhD, Fuad ElHibri. June 2019

Recognition for COVID-19 Groundbreaking research

2020 Recipient: The 2020 recipient is Dr. Emily S. Gurley, from the Department of Epidemiology for leading the Novel Coronavirus Research Compendium project.

Dr. Gurley has worked in public health research in Bangladesh since 2003, and she spent 12 years at the icddr,b (International Center for Diarrheal Diseases Research, Bangladesh) where she led the Surveillance and Outbreak Investigation Unit, and served as Director of the Program on Emerging Infections. She worked closely with the US CDC and the Government of Bangladesh to establish national surveillance for meningo-encephalitis, respiratory infections, acute gastroenteritis, acute hepatitis, and hospital acquired infections, with a focus on developing junior scientists.

Dr. Gurley leads multi-disciplinary studies on the transmission, burden and epidemiology of a variety of emerging and vaccine preventable diseases, taking into account the ecological context in which human disease occurs. Her interests include improving the communication and collaboration between field epidemiologists and infectious disease modelers and development of novel surveillance and outbreak detection strategies. She has been working to describe the ecology and epidemiology of Nipah virus since 2004, including identifying transmission pathways and drivers of person-to-person transmission, and designing and testing interventions to prevent human infection. She currently serves on WHO's Nipah Virus Taskforce, advising on the research and development of medical countermeasures. Her research adopts a One Health approach to the study and prevention of infectious disease, taking into account the ecological context in which human disease occurs. Emily is the Co-Director for the Child Health and Mortality Prevention Surveillance (CHAMPS) site in Bangladesh, aiming to determine the etiology of and prevent child deaths. She also works closely with the US Centers for Disease Control and Prevention's Global Disease Detection program.

When the COVID-19 pandemic began, she drew upon her many years of experience in public health research and practice in infectious diseases and teaching to support pandemic response efforts. She is the lead instructor for two popular, free Coursera courses on contact tracing for COVID-19 with more than 650,000 students enrolled since May.

Emily also co-leads the Novel Coronavirus Research Compendium project, an effort of nearly 50 faculty and trainees, which reviews and summarize a curated set of COVID-19 related research papers to keep frontline clinicians and public health professionals informed about the current state of the evidence on the clinical presentation, epidemiology, diagnostics, therapeutics, non-pharmaceutical interventions, modeling, and ecology of SARS-CoV-2. She is an expert consultant for the World Health Organization on the transmission of SARS-CoV-2, has co-authored pandemic response plans and scientific briefs, and supports numerous health departments and organizations on SARS-CoV-2 transmission and control.

Emily Gurley
Emily S. Gurley PhD.
Associate scientist in the division of infections disease epidemiology at the Johns Hopkins Bloomberg School of Public Health


Impact of the Shikani-El Hibri Prize for Discovery & Innovation

"Thank you. By supporting our faculty, you provided them opportunities to improve health locally and worldwide. We are forever grateful for the legacy you have created at the Johns Hopkins Bloomberg School of Public Health." - Dean Ellen MacKenzie, PhD '79, MSc '75

Awarded to full-time JHSPH professorial or scientist faculty members, at any rank, who conduct bench science research in the laboratory-based departments (i.e., MBM, MMI & EHS). The prize will be awarded for a discovery that is either currently in press or has been published within the last five years. The relevant work must have been performed while at JHSPH Technology; transfer activities (e.g., patents) conducted within the same timeframe are also eligible. The recipient will be determined by a committee of peers and based on the discovery's significance, innovation, and potential for public health impact.

2014 Recipient: Jiou Wang

Jiou WangJiou Wang, MD is an associate professor in the Department of Biochemistry and Molecular Biology. His long-standing interest is to uncover the basic molecular and cellular processes underlying age-related human neurodegenerative diseases. He is a pioneer in the studies of protein and RNA homeostasis as well as mechanisms of amyotrophic lateral sclerosis and frontotemporal dementia. Wang's team recently discovered novel pathways of protein quality control and stress responses, which could be potentially harnessed to defend against neurodegeneration in the efforts of developing effective strategies to face the growing public health challenge.

2015 Recipient: Scott Bailey

Scott BaileyScott Bailey, PhD is an associate professor in the Department of Biochemistry and Molecular Biology. He is a biochemist whose research seeks to understand the molecular basis of CRISPR. CRISPR has emerged as a powerful and versatile molecular tool for precise genome editing applications in basic research, biotechnology, and medicine. Bailey is currently applying state-of-the-art single-molecule techniques to further our understanding of CRISPR. In particular, he is using cryo-electron microscopy, a technique that allows the visualization of individual molecules, to probe how CRISPR targets specific DNA sequences. Results from these studies will not only further our basic understanding of biology but hopefully pave the way for improved CRISPR tools.

2016 Recipient: Andy Pekosz

Andy PekoszAndrew Pekosz, PhD is a tenured professor in the W. Harry Feinstone Department of Molecular Microbiology and Immunology. His research interests have focused on influenza and other respiratory viruses and, in particular, the ability of these viruses to infect and replicate in the upper respiratory tract. His laboratory uses primary, differentiated human nasal epithelial cell cultures to identify novel mutations that improve the ability of viruses to replicate in this important part of the respiratory tract. This work has also led to the realization that the host response to infection can change drastically when infection occurs at the cooler temperatures of the upper respiratory tract when compared to the lower respiratory tract. He is Co-director of the Johns Hopkins Center of Excellence in Influenza Research and Surveillance, Director of the Center for Emerging Viruses and Infectious Diseases, and the current President of the American Society for Virology.

2017 Recipient: Daniela Drummond-Barbosa

Daniela Drummond-BarbosaDaniela Drummond-Barbosa, PhD is a tenured professor in the Department of Biochemistry and Molecular Biology at the Bloomberg School of Public Health. Drummond-Barbosa received her PhD from Yale University and pursued her postdoctoral training at the Carnegie Institution for Science, where she pioneered using Drosophila melanogaster as a model to study how diet regulates adult tissue stem cells. Her laboratory at Vanderbilt University (2002-2009) and at the Bloomberg School (2009-present) identified several mechanisms involving insulin-like peptides, the steroid hormone ecdysone, the nutrient sensor Target of Rapamycin (TOR), and other diet-regulated pathways that modulate germline stem cells (GSCs) and their differentiating progeny. More recently, Drummond-Barbosa's group discovered that adipocyte-specific disruption of amino acid transport, TOR or insulin signaling causes distinct GSC lineage phenotypes and that diet controls multiple metabolic pathways within adipocytes that can influence specific processes in the GSC lineage. Her team is also actively investigating how obesity and other forms of chronic stress affect stem cell lineages. Her group's research points to extensive communication between adipocytes and the ovary, and underscores the complexity of the physiological network that modulates stem cell behavior according to dietary constraints, obesity, and other stresses. She is an elected fellow of the American Association for the Advancement of Science and serves as a regular study section member for the National Institutes of Health.

2018 Recipient: George Dimopoulos

George DimopoulosGeorge Dimopoulos, PhD is a tenured professor in the Department of Molecular Microbiology and Immunology at the Bloomberg School of Public Health. His research has advanced with the creation of new genetically-modified Anopheles and Aedes mosquito strains that are resistant to the malaria parasite Plasmodium ad dengue and Zika viruses, respectively. His group is now assessing the fitness of these mosquitoes along with testing their resistance to multiple pathogen strains. The long-term goal is to create mosquitoes that won't transmit these human pathogens as part of an integrated vector-borne disease control strategy.

2019 Recipient: Anthony K. L. Leung

Anthony LeungAnthony Leung PhD - a scientist and an inventor - is an expert in the area of RNA, ADP-ribosylation and proteomics. Dr. Leung completed his four-year Master in Biochemistry degree at the Exeter College, University of Oxford. Funded by the Croucher Scholarship from Hong Kong and Overseas Research Scheme from United Kingdom, Dr. Leung earned his Ph.D. in Biochemistry from the University of Dundee under the guidance of Dr. Angus I. Lamond. Using quantitative proteomes and imaging approaches, Dr. Leung characterized the nucleolar proteome dynamics and discovered a novel nucleolar localization pathway during his Ph.D. In 2004, Dr. Leung was awarded the Human Frontier Science Program Long-term Fellowship and, subsequently in 2007, a Special Fellowship from The Leukemia & Lymphoma Society to perform postdoctoral research on microRNAs under the mentorship of Nobel Laureate Dr. Phillip A. Sharp at MIT. In 2010, Dr. Leung hold a secondary postdoctoral appointment with Dr. Paul Chang at MIT on investigating a therapeutically important protein modification called ADP-ribosylation. Dysregulation of ADP-ribosylation metabolism results in neurodegenerative disorders, virus infection and cancer susceptibility.

2020 Recipient: Emily S. Gurley

Emily GurleyDr. Gurley is an associate scientist in the division of infections disease epidemiology at the Johns Hopkins Bloomberg School of Public Health. When the COVID-19 pandemic began, she drew upon her many years of experience in public health research and practice in infectious diseases and teaching to support pandemic response efforts. She is the lead instructor for two popular, free Coursera courses on contact tracing for COVID-19 with more than 650,000 students enrolled since May. Emily also co-leads the Novel Coronavirus Research Compendium project, an effort of nearly 50 faculty and trainees, which reviews and summarize a curated set of COVID-19 related research papers to keep frontline clinicians and public health professionals informed about the current state of the evidence on the clinical presentation, epidemiology, diagnostics, therapeutics, non-pharmaceutical interventions, modeling, and ecology of SARS-CoV-2. She is an expert consultant for the World Health Organization on the transmission of SARS-CoV-2, has co-authored pandemic response plans and scientific briefs, and supports numerous health departments and organizations on SARS-CoV-2 transmission and control.


Alan H Shikani MD, FASC is elected President of the Crowe Johns Hopkins Alumni ENT Society, 2014-2017

Crowe Society

The Johns Hopkins Crowe Society

The purpose of the Johns Hopkins Crowe Society is:

  1. To assist The Johns Hopkins residents in training in the Department of Otolaryngology-Head and Neck Surgery at the Johns Hopkins University and to achieve excellence by supporting their research and educational activities.
  2. To advance the art and science of otolaryngology by promoting educational, scientific, and community functions.
  3. To encourage fellowship among the alumni and faculty of the department of Otolaryngology-Head and Neck Surgery of the Johns Hopkins University.

The baton has been passed. The Crowe Society has a new President.

By Alan H. Shikani MD, FACS

It has been said "It is not enough to run the race. We also must pass the baton and must do it well." And what a baton it was: the Crowe Society Gavel was formidable and impressive, as was the task of running a Society of extraordinary JHU otolaryngologists. In reality, I feel that this is not a race; and that there is no finish line. It is continuous team effort and the goal is to support the residents and keep the Crowe fellowship alive.

The team worked well together, and the Society is thriving. We have raised the Crowe Education Fund to an amazing level of $437,339. The donations at the Centennial Campaign totaled $275,000. Every year, $14,000 in interest goes towards the Crowe goals of residents' education, equipment, stipends and social events. We have raised $93,000 for the Department's Temporal Bone Lab, just in our first fundraising year. The goal is a total of $200,000 over 3 years. Once this goal is reached, the lab will be named the "Crowe Society Lab." We have created an effective private platform for communication and networking among the Crowe members and jump-started 4 different Crowe ventures:

The Crowe members will have the opportunity to share their experience in medical volunteering, to tell about their Otolaryngology innovation, to link up to enjoy common social interests and hobbies, and to share their Crowe memories and photographs. We have worked closely with the chairman of the Department of OLHNS, Dr. David Eisele, who helped the Society navigate the Hopkins politics, not a simple thing to do; and we did it with grace and perseverance.

It has been a pleasure and a privilege to serve as president of the Crowe Society. I have learned a lot and I have had a wonderful time. My appreciation and gratitude go to the members of the 2014-2017 Executive Committee, without whom we could not have done it. Many thanks to our treasurer Dr. Ira Papel for managing the finances of the Society, and to our councilmen-at-large Drs. John Price and Roy Schottenfeld for their steadfast assistance with brainstorming, planning, social networking, and much more; together they have made our tenure a success. Special thanks to our administrative coordinator Donna Clare for helping with the communication among the members and the Department and with electronic voting of the Crowe officers & fundraising, and to Sara Levy from DocMatter for her assistance in setting up the Crowe Society website.

We have completed our task and we successfully pass the baton to the next generation of Crowe Officers. The mission is alive and the Crowe Society marches on!

Alan Shikani MD (1984-1991)
President, Crowe Society 2014-2017

New Crowe Society president


The COVID-19 PANDEMIC

LAI International and Alan H. Shikani MD team up to manufacture and deliver 1500 COVID-19 medical face shields to Baltimore area hospitals and private medical practices.

Westminster, Maryland, April 24, 2020 - Early days of the COVID19 pandemic.

LAI International, a global leader in advanced manufacturing technology for the aerospace, defense, medical, and industrial sectors teamed up with Dr. Alan H. Shikani, who is the Chief of Otolaryngology-Head and Neck Surgery at MedStar Union Memorial Hospital and LifeBridge Sinai Hospital in Baltimore and founder of The Airway Company, to develop the clinically tested reusable face shield. The team was able to design, retool manufacturing equipment, complete R&D, and conduct clinical trials to deliver 1500 shields to seven hospitals and medical centers in less than two weeks.

Shikani Gol COVID

Dr. Alan H. Shikani and Dr. Abraham Gol and of MedStar Union Memorial and LifeBridge Sinai Hospitals evaluate the new COVID-19 face shields.

Inspecting face shield

Kyle Duble, Forrest Rosenbloom, and Marlon Johnson of LAI inspect a face shield assembly.

With the surge of COVID-19 patients, hospitals across the country have been experiencing a dangerous shortage of personal protective equipment (PPEs) for healthcare workers such as face shields, masks, gowns, and gloves. Dr. Shikani partnered with LAI and the Airway Company to design an optimal face shield that would protect health care providers who are potentially exposed to the coronavirus. "LAI International is proud to help support our local communities. The health and safety of our employees and their families is our number one priority," said Mr. Johnson. "We worked hand in hand with Shannon Van Deren, President of Layered Manufacturing, to retool our aerospace and defense facility to produce face shields. It was no easy task, and our team stand ready to assist our country in any way it can."

"We greatly appreciate this timely donation as we continue to have supply chain concerns regarding personal protection. This gear is a big help in protecting our team," said Dr. Dave Eisele, Chairman of the Department of Otolaryngology - Head and Neck Surgery at the Johns Hopkins Medical Institutions.

The face shields were delivered to Medstar Union Memorial, MedStar Good Samaritan, and MedStar Georgetown Hospitals; LifeBridge Health Sinai and Carroll Hospitals; Johns Hopkins University Medical Institutions; and University of Maryland Medical Institutions.

Donna Clare, Director of Development, Otolaryngology - Head and Neck Surgery at Johns Hopkins Medicine commented, "Your donation no doubt will save lives - of our healthcare colleagues."

About LAI International

LAI International is premier provider of highly engineered, mission-critical components since 1979, and is renowned for our cutting-edge precision component manufacturing and solutions. LAI is AS9100 Rev D certified and meets our customers' production goals by delivering high quality complex components for the aerospace, defense, and medical industries on time, every time, at the right value. For more information, please visit https://www.laico.com.

About the Airway Company Inc.

The Airway Company is medical device company that was founded by Dr Shikani and that is dedicated to designing innovative products for tracheotomy patients, in order to make speech attainable, make breathing easier, restore pulmonary health, and improve the tracheotomy patient's quality of life. The Airway Company manufactures filters that can be used with the medical face shields. For more information, please visit https://www.theairwaycompany.com.


LAI International and Alan H. Shikani MD team up to design a new Positive Airway Pressure Respirator (PAPR), which functions as a Personal Protective Equipment (PPE) that provides protection to Health Care workers against COVIS-19.

Baltimore, Maryland, July 2020. Mid-COVID19 pandemic.

Dr. Alan H. Shikani, the Chief of Otolaryngology-Head and Neck Surgery at MedStar Union Memorial Hospital and LifeBridge Sinai Hospital and founder of the Airway Company is teaming up with LAI International, a global leader in advanced manufacturing technology for the aerospace, defense, medical, in order to develop a new Positive Airway Pressure Respirator (PAPR) which functions as a personal protective equipment (PPE) device that protect the healthcare workers' face and associated mucous membranes (eyes, nose, mouth) from splashes, sprays, and spatter of body fluids.

PAPR

Dr Alan Shikani is evaluating the novel Positive Airway Pressure Respirator (PAPR).

PAPR

Dr Alan Shikani assessing the upper airway using the novel Positive Airway Pressure Respirator (PAPR).

The face shield's visor is lightweight and balanced for all day comfort and has an ergonomic design with full face 180-degree visibility; it is made with shatter proof/ scratch resistant/ antifog material (such as polycarbonate).

The shield is fit with a unique filtration system, an HME filter on each side of the visor that contains hygroscopic media made of porous reticulated ester-type polyurethane foam and an additional layer of N95 material, which filters breathed air from unwanted particles and infectious germs and similar particulates from the environment. The novel face shield-mask includes a visor with two attachment hubs on each side so that filters can be attached to the frame of the helmet.

PAPR PAPR PAPR PAPR

One novelty of this face shield is its unique inflow port for delivery of air which will provide a two-fold advantage of improved ventilation to the user and a special air circulation system inside the masks to ensure enhanced defogging of the front visor. A strap helps securing the mask to the head of the user, the strap could optionally be elastic bands or Velcro.